Brachytherapy for prostate cancer in 2010

Abstract

Permanent prostate brachytherapy by implantation of radioactive isotope seeds has become a widely accepted treatment modality for localized prostate cancer. Clinical outcome data are mature and show excellent long-term PSA recurrence-free survival over 10 years in patients with low risk tumours. Results are dependent on patient selection and implant quality. Preservation of erectile function can be achieved in younger previously potent men and aided by medical treatment. Prostatic neoplasms - Brachytherapy - Prostatespecific antigen - Erectile function.